Leiden University Scholarly Publications

Persistent URL of this record https://hdl.handle.net/1887/3181518

In Collections

This item can be found in the following collections:

Smolle, M.A.; Schaffler, A.; Leithner, A.; Praag, V.M. van; Bergovec, M.; Szkandera, J.; ... ; Andreou, D. (2020)

Incidence, treatment and outcome of abdominal metastases in extremity soft tissue sarcoma: results from a multi-centre study

Article / Letter to editor
Background and Objectives Abdominal metastases (AM) from soft tissue sarcoma (STS) are rare and prognosis is poor. The aims of the study were to (a) identify risk factors for the development of AM and to (b) investigate the outcome of AM-patients. Methods Seven-hundred-sixty-nine STS-patients with localised disease at diagnosis treated at three tumour centres (2000-2016) were retrospectively included (409 males; mean age, 55.6 years [range, 8-96 years]; median follow-up, 4.1 years [interquartile-range, 2.5-6.6 years]). Results Two-hundred-two patients (26.3%) developed secondary metastases, and 24 of them AM (3.1%). Ten patients developed first AM (FAM) after a mean of 2.4 years and 14 patients late AM (LAM, after being diagnosed with metastases to other sites) after a mean of 2.0 years. Patients with liposarcoma had a significantly higher risk of developing AM (P = .007), irrespective of grading. There was no difference in post-metastasis-survival (PMS) between patients with AM at...Show moreBackground and Objectives Abdominal metastases (AM) from soft tissue sarcoma (STS) are rare and prognosis is poor. The aims of the study were to (a) identify risk factors for the development of AM and to (b) investigate the outcome of AM-patients. Methods Seven-hundred-sixty-nine STS-patients with localised disease at diagnosis treated at three tumour centres (2000-2016) were retrospectively included (409 males; mean age, 55.6 years [range, 8-96 years]; median follow-up, 4.1 years [interquartile-range, 2.5-6.6 years]). Results Two-hundred-two patients (26.3%) developed secondary metastases, and 24 of them AM (3.1%). Ten patients developed first AM (FAM) after a mean of 2.4 years and 14 patients late AM (LAM, after being diagnosed with metastases to other sites) after a mean of 2.0 years. Patients with liposarcoma had a significantly higher risk of developing AM (P = .007), irrespective of grading. There was no difference in post-metastasis-survival (PMS) between patients with AM at any time point and those with metastases to other sites (P = .585). Patients with LAM or FAM showed no difference in post-abdominal-metastasis-survival (P = .884). Conclusions Survival in patients with AM is poor, irrespective of whether they develop secondarily to other metastases or not. Patients at high-risk of AM (ie, liposarcoma) may be followed-up regularly by abdominal-ultrasound/CT.Show less
abdominal metastasis
soft tissue sarcoma
survival
All authors
Smolle, M.A.; Schaffler, A.; Leithner, A.; Praag, V.M. van; Bergovec, M.; Szkandera, J.; Liegl-Atzwanger, B.; Niethard, M.; Tunn, P.U.; Sande, M. van de; Andreou, D.
Date
2020-01-31
Journal
Journal of Surgical Oncology
Volume
121
Issue
4
Pages
605 - 611
DOI
doi:10.1002/jso.25856
Link
https://onlinelibrary.wiley.com/doi/10.1002/jso.25856